FOLD241220C6000
- 0.00
- 0.000.00%
Amicus Therapeutics Newsroom
Amicus Therapeutics Cut to Equal-Weight From Overweight by Morgan Stanley
Morgan Stanley Downgrades Amicus Therapeutics(FOLD.US) to Hold Rating, Cuts Target Price to $12
J.P. Morgan Maintains Amicus Therapeutics(FOLD.US) With Buy Rating, Announces Target Price $17
J.P. Morgan Maintains Amicus Therapeutics(FOLD.US) With Buy Rating
A Quick Look at Today's Ratings for Amicus Therapeutics(FOLD.US), With a Forecast Between $15 to $21
Amicus Therapeutics Is Maintained at Buy by Guggenheim
Cantor Fitzgerald Maintains Overweight on Amicus Therapeutics, Raises Price Target to $21
A Quick Look at Today's Ratings for Amicus Therapeutics(FOLD.US), With a Forecast Between $15 to $20
Amicus Therapeutics Analyst Ratings
Amicus Therapeutics: Strong Financial Performance and Growth Prospects Justify Buy Rating
TD Cowen Maintains Amicus Therapeutics(FOLD.US) With Buy Rating, Maintains Target Price $20
BofA Securities Maintains Amicus Therapeutics(FOLD.US) With Buy Rating, Raises Target Price to $15
B of A Securities Maintains Buy on Amicus Therapeutics, Raises Price Target to $15
Amicus Therapeutics Is Maintained at Overweight by Morgan Stanley
Amicus Therapeutics Analyst Ratings
Morgan Stanley Maintains Amicus Therapeutics(FOLD.US) With Buy Rating, Cuts Target Price to $18
Amicus Therapeutics Price Target Maintained With a $20.00/Share by Cantor Fitzgerald
Jefferies Initiates Amicus Therapeutics(FOLD.US) With Buy Rating, Announces Target Price $18
Amicus Therapeutics Analyst Ratings
JP Morgan Maintains Overweight on Amicus Therapeutics, Lowers Price Target to $16